[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363081-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","inhibition-of-prmt5-triggers-synthetic-lethality-in-arid1a-deficient-endometrial-cancer-by-promoting-aberrant-r-loop-accumulation","Inhibition of PRMT5 triggers synthetic lethalityin ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation","","Endometrial cancer remains lethal in advanced disease, where 5-year survival stays below 20%, creating a need for new therapeutic options. ARID1A, a SWI/SNF chromatin remodeling subunit frequently mutated in endometrial cancer, offers a route to synthetic lethal targeting. This study identifies PRMT5 inhibition as a synthetic lethal strategy for ARID1A-deficient tumors and dissects the molecular basis through R-loop accumulation, DNA damage, and apoptosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inhibition-of-prmt5-triggers-synthetic-lethality-in-arid1a-deficient-endometrial-cancer-by-promoting-aberrant-r-loop-accumulation/363081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inhibition-of-prmt5-triggers-synthetic-lethality-in-arid1a-deficient-endometrial-cancer-by-promoting-aberrant-r-loop-accumulation/363081.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central therapeutic strategy investigated in this study?","Question",{"text":63,"@type":64},"The study evaluates inhibition of PRMT5 as a synthetic lethal approach specifically for ARID1A-deficient endometrial cancer by disrupting R-loop homeostasis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PRMT5 inhibition affect ARID1A-deficient endometrial cancer cells?",{"text":68,"@type":64},"PRMT5 inhibition promotes DNA damage, apoptosis, and accumulation of R-loops in ARID1A-deficient cells, supporting synthetic lethality.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular mechanism links ARID1A, PRMT5, and R-loop resolution?",{"text":72,"@type":64},"ARID1A directly regulates PRMT5 transcription; loss of ARID1A reduces PRMT5, impairs arginine methylation, and hinders DHX9-mediated R-loop recruitment and resolution, driving lethal R-loop buildup.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363081,1790175807,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Shu et al. Molecular Cancer (2026) 25:107 Molecular Cancer  \n[https://doi.org/10.1186/s12943-026-02629-2](https://doi.org/10.1186/s12943-026-02629-2)  \nRESEARCH Open Access  \nInhibition of PRMT5 triggers synthetic lethalityin ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation  \nWan Shu1†, Kejun Dong1†, Xiaoyu Shen1†, Xing Zhou1, Jiarui Zhang1, Shuyang Yu1, Shuangshuang Cheng1, Tangansu Zhang1, Guanxiao Chen1, Guanglei Zhong1, Jun Zhang1* and Hongbo Wang1*  \nAbstract  \nBackground Endometrial cancer (EC) is a common malignancy of the female reproductive system. The 5-year survival rate for advanced-stage EC patients is less than 20%, highlighting an urgent need for novel therapeutic strategies. ARID1A, a key subunit of the SWI/SNF chromatin remodeling complex, is one of the most frequently mutated genes in EC, presenting a potential avenue for synthetic lethal targeting of ARID1A-deficient EC. This study aims to identify novel synthetic lethal targets for ARID1A-deficient EC and to elucidate the underlying molecular mechanisms, thereby providing new insights for clinical treatment.  \nMethods The PRMT5 inhibitor JNJ-64,619,178 was identified via high-throughput compound screening as effectively inducing synthetic lethality in ARID1A-deficient EC cells. RNA-seq, comet assays, immunofluorescence, and Dot-blot experiments were employed to investigate DNA damage and R-loop accumulation. IP-MS, Co-IP, and proximity ligation (PLA) assays were used to detect interactions within the PRMT5-DHX9-R-loop axis. Chromatin immunoprecipitation‒PCR (ChIP‒PCR) experiments and dual luciferase reporter assays were performed to confirm that ARID1A directly transcriptionally regulates PRMT5 . The synthetic lethal effect between PRMT5 inhibition and ARID1A loss was further validated using EC xenograft mouse models and patient-derived organoid models (PDOs) . Results In this study, based on high-throughput drug screening, we identified that the PRMT5 inhibitor JNJ- 64,619,178 exerts a significant synthetic lethal effect on ARID1A-deficient EC. PRMT5 inhibition promoted DNA damage, apoptosis, and R-loop accumulation in ARID1A-deficient EC. This synthetic lethality was confirmed in  \nEC mouse models and PDOs. Mechanistically, we identified an association between ARID1A, PRMT5, and DHX9 . Mechanistically, ARID1A directly binds the PRMT5 promoter and regulates its expression. ARID1A loss downregulates PRMT5, impairing arginine methylation and R-loop recruitment of DHX9—a key factor in R-loop resolution.  \n†Wan Shu, Kejun Dong and Xiaoyu Shen contributed equally to this work.  \n*Correspondence: Jun Zhang [dr_zhangjun@hust.edu.cn](dr_zhangjun@hust.edu.cn)[ ](dr_zhangjun@hust.edu.cn)Hongbo Wang [drwanghb69@hust.edu.cn](drwanghb69@hust.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.","cbCaip4t42Ts0dOz","https://ap.wps.com/l/cbCaip4t42Ts0dOz","pdf",13222871,26,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Endometrial cancer burden and treatment limitations\n## Concept of synthetic lethality","[{\"question\":\"What is the central therapeutic strategy investigated in this study?\",\"answer\":\"The study evaluates inhibition of PRMT5 as a synthetic lethal approach specifically for ARID1A-deficient endometrial cancer by disrupting R-loop homeostasis.\"},{\"question\":\"How does PRMT5 inhibition affect ARID1A-deficient endometrial cancer cells?\",\"answer\":\"PRMT5 inhibition promotes DNA damage, apoptosis, and accumulation of R-loops in ARID1A-deficient cells, supporting synthetic lethality.\"},{\"question\":\"What molecular mechanism links ARID1A, PRMT5, and R-loop resolution?\",\"answer\":\"ARID1A directly regulates PRMT5 transcription; loss of ARID1A reduces PRMT5, impairs arginine methylation, and hinders DHX9-mediated R-loop recruitment and resolution, driving lethal R-loop buildup.\"}]","Inhibition of PRMT5 triggers synthetic lethalityin ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation | PDF",1790149932,66,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d810fdc1d819970c7067c197e5dbb17d.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4201d31474da066c1f2b821b95938a0.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/174089986b6b8cf190bd4a631ee8593e.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d261027980a5a74868016efe42aa36e.webp",980,1306]